Cash for new class

With antibiotics back in focus for investors, Nabriva Therapeutics AG attracted a handful of U.S. crossover investors for a $120 million series B round that should not only fund the antibiotic company through to commercialization, but also give it the option of going public in the near term.

On April 7, Nabriva raised $50 million in the first tranche of the $120 million round led by new investors Vivo Capital and OrbiMed. New investors EcoR1 Capital and Boxer Capital of Tavistock Life Sciences also participated. So did existing investors HBM Partners, Phase4 Partners, The Wellcome Trust, Global Life Science Ventures and Novartis Venture Fund...